GeneCentric is one of only 13 companies selected to participate at this year’s CED Life Science Conference Showcase. Dr. Myla Lai-Goldman, CEO of GeneCentric, will be presenting an overview of the company’s science and business model. The presentation will take place on Tuesday, March 3rd at 4:10pm at the Convention Center in Raleigh, North Carolina.
On November 15, 2014, at the annual Association of Molecular Pathology meeting in Maryland just outside Washington DC, GeneCentric presented a validation study of its Lung Cancer Gene Expression Subtyping Panel (LSP) using RT-qPCR of formalin fixed paraffin embedded samples.
The LSP gene signature has been shown to be a robust method for classifying lung tumors and demonstrates good concordance with morphology classification in multiple datasets. Gene expression profiling may supplement morphologic assessment in lung tumors particular in those that are difficult to classify. Additional details of the poster can be viewed here.
GeneCentric will present a poster entitled “Evaluation of a Lung Cancer RNA Expression Subtyping Panel and Comparison with Histologic Diagnosis in Lung Tumor Samples from Multiple Data Sets Including The Cancer Genome Atlas (TCGA)” at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) at 1:15 PM on Saturday May 31, 2014. The abstract is available online: http://abstracts.asco.org/144/AbstView_144_133228.html
Dr. Myla Lai-Goldman was recently interviewed by CEOCFO Magazine about the GeneCentric technology known as the Lung Subtype Platform. The October 15th issue covers the importance of subtype determination in lung cancer and how the GeneCentric LSP-TM test can fulfill an unmet medical need.
September 26, 2012- Durham, NC. GeneCentric, a molecular diagnostics company focused on personalized oncology today announced the appointment of Dr. Arnold Levine to the company’s board of directors. Dr. Levine brings to GeneCentric a wealth of experience related to the life sciences, and status as a prominent inventor in the field of molecular biology.
“I am pleased to join the GeneCentric Board at this important time for both the company and personalized oncology,” said Dr. Levine. “GeneCentric has brought together world leaders in cancer research and diagnostics. They have made tremendous progress in a very short amount of time to advance the development of novel, targeted assays that enable oncologists make more informed, individualized, therapy decisions.”
Dr. Levine is a widely acclaimed leader in cancer research. In 1979, Levine and others discovered the p53 tumor suppressor protein, a molecule that inhibits tumor development. Dr. Levine previously served as President and Chief Executive Officer of Rockefeller University from 1998 to 2002 and was the Harry C. Weiss Professor of the Life Sciences and Chairman of the Molecular Biology Department at Princeton University from 1984 to 1998. He established the Simons Center for Systems Biology at the Institute for Advanced Study, which concentrates on research at the interface of molecular biology and the physical sciences: on genetics and genomics, polymorphisms and molecular aspects of evolution, signal transduction pathways and networks, stress responses, and pharmacogenomics in cancer biology.
The Lung Subtype Platform (LSPTM) Holds Promise for Stratifying Lung Cancer while the Hypoxia Signature Has the Potential to Identify Patients that Could Respond to Anti-Angiogenesis Therapies
August 30, 2012 – Durham, NC. GeneCentric announced today that it has been launched with two separate exclusive licenses to diagnostic technologies from the University of North Carolina at Chapel Hill. The company was co-founded in 2011 by two pioneers in cancer research, Drs. Charles Perou and Neil Hayes, who discovered molecular signatures critical in distinguishing clinically relevant subtypes of lung cancer.
GeneCentric in-licensed the Lung Subtype Platform (LSPTM) from UNC-Chapel Hill based upon data demonstrating that the LSPTM technology can distinguish multiple subtypes of lung cancer based upon a genetic fingerprint from a tumor sample. These results were first published in the Journal of Clinical Oncology in 2006, with additional publications over the past 2 years.
Continue reading GeneCentric Diagnostics Launches with Exclusive Licenses from UNC-Chapel Hill for Two Diagnostic Platform Technologies